17-7220033-C-T

Variant summary

Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BA1BP4

This summary comes from the ClinGen Evidence Repository: The c.49C>T variant in ACADVL has been reported as part of premature screening panels, however no probands have shown increased VLCAD activity or newborn screening (PMID:23480858). The highest population minor allele frequency in gnomAD v2.1.1 is 0.06989 in the African population, which is higher than the ClinGen ACADVL Variant Curation Expert Panel threshold (≥0.007) for BA1, and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.236, which is below the threshold of 0.5, evidence that does not predict a damaging effect on ACADVL function (BP4). In summary, this variant meets criteria to be classified as benign for very long chain acyl-CoA dehydrogenase deficiency in an autosomal recessive manner. ACADVL-specific ACMG/AMP criteria applied: BA1; BP4 LINK:https://erepo.genome.network/evrepo/ui/classification/CA341522/MONDO:0008723/021

Frequency

Genomes: 𝑓 0.019 ( 100 hom., cov: 33)
Exomes 𝑓: 0.0019 ( 78 hom. )

Consequence

ACADVL
NM_000018.4 missense

Scores

18

Clinical Significance

Benign reviewed by expert panel B:13

Conservation

PhyloP100: -0.916
Variant links:
Genes affected
ACADVL (HGNC:92): (acyl-CoA dehydrogenase very long chain) The protein encoded by this gene is targeted to the inner mitochondrial membrane where it catalyzes the first step of the mitochondrial fatty acid beta-oxidation pathway. This acyl-Coenzyme A dehydrogenase is specific to long-chain and very-long-chain fatty acids. A deficiency in this gene product reduces myocardial fatty acid beta-oxidation and is associated with cardiomyopathy. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -9 ACMG points.

BP4
For more information check the summary or visit ClinGen Evidence Repository.
BA1
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
ACADVLNM_000018.4 linkuse as main transcriptc.49C>T p.Leu17Phe missense_variant 1/20 ENST00000356839.10 NP_000009.1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
ACADVLENST00000356839.10 linkuse as main transcriptc.49C>T p.Leu17Phe missense_variant 1/201 NM_000018.4 ENSP00000349297 P1P49748-1

Frequencies

GnomAD3 genomes
AF:
0.0191
AC:
2900
AN:
152170
Hom.:
100
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0657
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00779
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000207
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000265
Gnomad OTH
AF:
0.0186
GnomAD3 exomes
AF:
0.00512
AC:
1174
AN:
229122
Hom.:
34
AF XY:
0.00387
AC XY:
488
AN XY:
125954
show subpopulations
Gnomad AFR exome
AF:
0.0699
Gnomad AMR exome
AF:
0.00381
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.000100
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000215
Gnomad OTH exome
AF:
0.00335
GnomAD4 exome
AF:
0.00195
AC:
2827
AN:
1452620
Hom.:
78
Cov.:
35
AF XY:
0.00170
AC XY:
1226
AN XY:
722688
show subpopulations
Gnomad4 AFR exome
AF:
0.0676
Gnomad4 AMR exome
AF:
0.00441
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.000105
Gnomad4 FIN exome
AF:
0.0000429
Gnomad4 NFE exome
AF:
0.000111
Gnomad4 OTH exome
AF:
0.00372
GnomAD4 genome
AF:
0.0191
AC:
2906
AN:
152288
Hom.:
100
Cov.:
33
AF XY:
0.0180
AC XY:
1340
AN XY:
74468
show subpopulations
Gnomad4 AFR
AF:
0.0657
Gnomad4 AMR
AF:
0.00778
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.000207
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000265
Gnomad4 OTH
AF:
0.0184
Alfa
AF:
0.00244
Hom.:
13
Bravo
AF:
0.0216
ESP6500AA
AF:
0.0641
AC:
280
ESP6500EA
AF:
0.000234
AC:
2
ExAC
AF:
0.00608
AC:
732
Asia WGS
AF:
0.00231
AC:
8
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:13
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Very long chain acyl-CoA dehydrogenase deficiency Benign:6
Benign, criteria provided, single submitterclinical testingWong Mito Lab, Molecular and Human Genetics, Baylor College of MedicineNov 01, 2019The NM_000018.3:c.49C>T (NP_000009.1:p.Leu17Phe) [GRCH38: NC_000017.11:g.7220033C>T] variant in ACADVL gene is interpretated to be Benign based on ACMG guidelines (PMID: 25741868). This variant has been reported. This variant meets the following evidence codes reported in the ACMG guidelines: BS1, BS2 -
Benign, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsDec 15, 2021- -
Benign, no assertion criteria providedclinical testingNatera, Inc.Sep 16, 2020- -
Benign, reviewed by expert panelcurationClinGen ACADVL Variant Curation Expert Panel, ClinGenSep 22, 2022The c.49C>T variant in ACADVL has been reported as part of premature screening panels, however no probands have shown increased VLCAD activity or newborn screening (PMID: 23480858). The highest population minor allele frequency in gnomAD v2.1.1 is 0.06989 in the African population, which is higher than the ClinGen ACADVL Variant Curation Expert Panel threshold (≥0.007) for BA1, and therefore meets this criterion (BA1). The computational predictor REVEL gives a score of 0.236, which is below the threshold of 0.5, evidence that does not predict a damaging effect on ACADVL function (BP4). In summary, this variant meets criteria to be classified as benign for very long chain acyl-CoA dehydrogenase deficiency in an autosomal recessive manner. ACADVL-specific ACMG/AMP criteria applied: BA1; BP4 -
Benign, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaJan 13, 2018This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -
Benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpFeb 01, 2024- -
not provided Benign:5
Benign, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesNov 03, 2017- -
Benign, criteria provided, single submitterclinical testingGeneDxMar 03, 2015- -
Benign, criteria provided, single submitterclinical testingCenter for Pediatric Genomic Medicine, Children's Mercy Hospital and ClinicsMay 14, 2015- -
Benign, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpMar 08, 2016Variant summary: c.49C>T affects a non-conserved nucleotide, resulting in amino acid change from Leu to Phe. 4/4 in-silico tools predict this variant to be benign .The variant was observed in the large and broad control population from ExAC with an allele frequency of 0.0071727% (648/90342 chromosomes) which includes 20 homozygous occurrences. The variant is particularly more common in African population with an allele frequency of 8.8% (597/6748 chromosomes) including 20 homozygotes. This frequency exceeds the maximal expected frequency of a pathogenic allele (0.288%) in this gene, suggesting this variant is benign polymorphism found mainly in African population. One reputable database and a clinical lab classify the variant as benign. Taken together, this variant has been classified as Benign. -
Benign, criteria provided, single submitternot providedBreakthrough Genomics, Breakthrough Genomics-- -
not specified Benign:2
Benign, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact Sciences-- -
Benign, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Mar 30, 2016- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.067
BayesDel_addAF
Benign
-0.39
T
BayesDel_noAF
Benign
-0.28
CADD
Benign
22
DANN
Benign
0.92
DEOGEN2
Benign
0.15
T;.;.;.;T
Eigen
Benign
-1.2
Eigen_PC
Benign
-1.2
FATHMM_MKL
Benign
0.0080
N
LIST_S2
Benign
0.64
T;T;T;T;T
MetaRNN
Benign
0.0017
T;T;T;T;T
MetaSVM
Benign
-0.36
T
MutationAssessor
Benign
1.6
L;.;L;.;.
MutationTaster
Benign
1.0
N;N;N;N
PrimateAI
Benign
0.44
T
PROVEAN
Benign
-0.42
.;.;N;.;.
REVEL
Benign
0.24
Sift
Benign
0.30
.;.;T;.;.
Sift4G
Benign
0.069
T;T;T;D;T
Polyphen
0.0
B;.;B;.;.
Vest4
0.28
MVP
0.74
ClinPred
0.016
T
GERP RS
-4.7
Varity_R
0.050

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.87
Details are displayed if max score is > 0.2
DS_DG_spliceai
0.87
Position offset: -2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs2230179; hg19: chr17-7123352; API